Taysha Gene Therapies(TSHA)

Search documents
Taysha Gene Therapies(TSHA) - 2021 Q4 - Earnings Call Transcript
2022-03-31 18:24
Taysha Gene Therapies (NASDAQ:TSHA) Q4 2021 Earnings Conference Call March 31, 2022 8:00 AM ET Company Participants RA Session II – President, Chief Executive Officer & Founder Kimberly Lee – Corporate Affairs Officer Suyash Prasad – Chief Medical Officer & Head, Research & Development Kamran Alam – Chief Financial Officer Conference Call Participants Elizabeth Webster – Goldman Sachs Joon Lee – Truist Securities Mike Ulz – Morgan Stanley Jack Allen – Baird Kevin DeGeeter – Oppenheimer Gil Blum – Needham an ...
Taysha Gene Therapies(TSHA) - 2021 Q4 - Annual Report
2022-03-31 13:06
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-39536 Taysha Gene Therapies, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 84-3199512 ( ...
Taysha Gene Therapies(TSHA) - 2021 Q3 - Quarterly Report
2021-11-10 21:29
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-39536 Taysha Gene Therapies, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 84- ...
Taysha Gene Therapies(TSHA) - 2021 Q3 - Earnings Call Transcript
2021-11-10 21:14
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q3 2021 Earnings Conference Call November 10, 2021 8:00 AM ET Company Participants Kimberly Lee - SVP, Corporate Communications & IR RA Session II - President, CEO & Founder Suyash Prasad - CMO & Head, R&D Kamran Alam - CFO Conference Call Participants Joon Lee - Truist Securities Gil Blum - Needham and Company Laura Chico - Wedbush Securities Elizabeth Webster - Goldman Sachs Mike Ulz - Morgan Stanley Kevin DeGeeter - Oppenheimer Yun Zhong - BTIG Kristen Kluska - C ...
Taysha Gene Therapies (TSHA) Investor Presentation - Slideshow
2021-09-10 18:19
Bringing New Cures to Life CLN1 Disease Investor Day August 30, 2021 | 9:00 — 11:30 AM CT : 0 . 1 : 1 0 . : : : | : ● ○ Ⅰ : ● … : | 0 · : 0 · | : ♥ 0 | Legal disclosure FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, future operations, future financial position, future revenues, projected cos ...
Taysha Gene Therapies(TSHA) - 2021 Q2 - Earnings Call Transcript
2021-08-16 19:06
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q2 2021 Earnings Conference Call August 16, 2021 8:00 AM ET Company Participants Kimberly Lee - Senior Vice President, Corporate Communications and Investor Relations RA Session II - President, Chief Executive Officer and Founder Suyash Prasad - Chief Medical Officer and Head, R&D Kamran Alam - Chief Financial Officer Conference Call Participants Elizabeth Webster - Goldman Sachs Joon Lee - Truist Securities Laura Chico - Wedbush Securities Gil Blum - Needham & Comp ...
Taysha Gene Therapies(TSHA) - 2021 Q2 - Quarterly Report
2021-08-16 12:36
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-39536 Taysha Gene Therapies, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 84-31995 ...
Taysha Gene Therapies(TSHA) - 2021 Q1 - Quarterly Report
2021-05-11 20:17
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-39536 Taysha Gene Therapies, Inc. (Exact Name of Registrant as Specified in its Charter) FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Delaware 84-3199 ...
Taysha Gene Therapies(TSHA) - 2021 Q1 - Earnings Call Transcript
2021-05-11 18:49
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q1 2021 Earnings Conference Call May 11, 2021 8:00 AM ET Company Participants Kimberly Lee – Senior Vice President of Corporate Communications and Investor Relations RA Session II – President, Founder, and Chief Executive Officer Suyash Prasad – Chief Medical Officer and Head-R&D Kamran Alam – Chief Financial Officer Fred Porter – Chief Technical Officer Conference Call Participants Salveen Richter – Goldman Sachs Raju Prasad – William Blair Eun Yang – Jefferies Ope ...
Taysha Gene Therapies (TSHA) Investor Presentation - Slideshow
2021-04-16 18:48
Bringing New Cures to Life TSHA-120 GAN Program Acquisition – Conference Call April 12, 2021 Legal disclosure FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forw ...